Celldex Therapeutics (CLDX) Stock Price
$22.02 0%
to add to portfolio
AI Score
-
Alternative
8 -
Fundamental
6 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Celldex Therapeutics, AI stock picks, stock alerts and much more.
CLDX AI Stock Analysis
AI stock analysis for CLDX is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Celldex Therapeutics (CLDX) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Celldex Therapeutics (CLDX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Celldex Therapeutics (CLDX), currently trading at $22.02, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About CLDX
-
Celldex Therapeutics, Inc.
-
Symbol
CLDX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
1.5B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$20.56 1.1% |
8 |
 |
Inovio Pharmaceuticals INO |
$1.91 3.2% |
3 |
 |
Moderna MRNA |
$26.22 2.5% |
3 |
 |
Anavex Life Sciences AVXL |
$9.55 1.3% |
5 |
 |
BridgeBio Pharma BBIO |
$50.23 2.8% |
6 |
News
CLDX Alternative Data
Web Traffic
Celldex Therapeutics receives an estimated 10571 monthly visitors to celldex.com.
-
Web Traffic
10571
-
Change from Previous Month
87.6%
-
3 Month Change
55.1%
-
YoY Change
55.1%
Twitter Followers
Celldex Therapeutics has 176 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.1% over the last month.
-
Twitter Followers
176
-
Daily Change
0%
-
1 Month Change
1.1%
-
3 Month Change
6%
-
YoY Change
6%
Facebook Engagement
Celldex Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Followers
12,468 are following Celldex Therapeutics on LinkedIn, up by 1.2% over the last month.
-
LinkedIn Followers
12468
-
Daily Change
0%
-
1 Month Change
1.2%
-
3 Month Change
3.7%
Job Postings
Celldex Therapeutics currenly has an estimated 12 open job postings, up by 71.4% over the last month.
-
Job Postings
12
-
Daily Change
0%
-
1 Month Change
71.4%
-
3 Month Change
100%
-
YoY Change
100%
LinkedIn Employees
According to LinkedIn, Celldex Therapeutics has 231 employees, up by 0.4% over the last month.
-
LinkedIn Employees
231
-
Daily Change
0.9%
-
1 Month Change
0.4%
-
3 Month Change
5.5%
-
YoY Change
5.5%
Reddit Mentions
Celldex Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Celldex Therapeutics is 76 out of 100 (bullish).
-
Business Outlook
76
-
Change from Previous Month
0%
-
3 Month Change
1.3%
-
YoY Change
1.3%
News Mentions
Celldex Therapeutics was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
50%
-
1 Month Change
0%
-
3 Month Change
0%
CLDX Financials
CLDX Key Metrics
-
Total Revenue
$1.2M
-
Net Income
-$47.1M
-
Earnings per Share
-$0.73
-
Free cash flow
-$33.2M
-
EBITDA
-$55.2M
-
EBITDA Ratio
-46.9855
-
Total Assets
$792.3M
CLDX 2-year Revenue & Income
CLDX 2-year Free Cash Flow
CLDX Technicals
CLDX SMA
CLDX RSI
FAQ
What's the current price of Celldex Therapeutics (CLDX) Stock?
The price of an Celldex Therapeutics (CLDX) share is $22.02.
What's the market cap of Celldex Therapeutics?
The current market cap of Celldex Therapeutics is 1.5B.
Should I buy or sell CLDX?
Multiple alternative data signals suggest that Celldex Therapeutics stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Celldex Therapeutics a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Celldex Therapeutics stock. The bullish indicators suggest that Celldex Therapeutics' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Celldex Therapeutics (CLDX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Celldex Therapeutics stock, given the bullish outlook.
What are some stocks similar to Celldex Therapeutics (CLDX) that investors often compare it to?
Celldex Therapeutics (CLDX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Celldex Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Celldex Therapeutics' stock price to be around $23.57 in 2026. Starting from the current price of $22.02, this represents a 7% change in price, indicating a bullish outlook for the stock.
How to buy Celldex Therapeutics (CLDX) Stock?
Celldex Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Celldex Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.